- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo, Nipocalimab, Standard-of-care treatment
- Other · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 21
- States / cities
- Los Alamitos, California • Rancho Mirage, California • Santa Ana, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 20,796
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- HIV Infections
- Interventions
- HIV Testing and Counseling, Contingency Management, Strengths-based case management
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- HIV Infections
- Interventions
- Ortho Tri-Cyclen LO, Ortho Cyclen, Ortho Cyclen + Efavirenz
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 2
- States / cities
- San Diego, California • Tacoma, Washington
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Betaferon/Betaseron
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 51
- States / cities
- Tucson, Arizona • Berkeley, California • Irvine, California + 46 more
- Conditions
- Graft vs Host Disease, Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
- Interventions
- Questionnaires, Blood Sample, Stool Sample, Clinical data
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Chronic Lymphoproliferative Diseases
- Interventions
- GRN163L
- Drug
- Lead sponsor
- Geron Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Hackensack, New Jersey • Buffalo, New York + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- Oprozomib, Lenalidomide, Dexamethasone, Cyclophosphamide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 14
- States / cities
- Huntsville, Alabama • Burbank, California • Los Angeles, California + 11 more
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, HIV (Human Immunodeficiency Virus)
- Interventions
- Resmetirom, Placebo Control
- Drug
- Lead sponsor
- Naga P. Chalasani
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 7 more
- Conditions
- Human Immunodeficiency Virus, Substance Use, Stigma, Social
- Interventions
- Harm Reduction
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 768 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Pittsburgh, Pennsylvania
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma
- Interventions
- NKX019
- Biological
- Lead sponsor
- Nkarta, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Cleveland, Ohio
- Conditions
- Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Interventions
- TAK-007, Chemotherapy Agents
- Biological · Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Systemic Amyloidosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies, Waldenström Macroglobulinemia
- Interventions
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 74 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Duarte, California • Stanford, California + 5 more
- Conditions
- HIV/AIDS
- Interventions
- Storytelling Narrative Intervention
- Combination Product
- Lead sponsor
- University of Massachusetts, Boston
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV-1, Fertility, Infertility
- Interventions
- Sperm Washing with Intrauterine Insemination (IUI)
- Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- ITP, Immune Thrombocytopenia
- Interventions
- Fostamatinib
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 14
- States / cities
- Tamarac, Florida • Springfield, Illinois • Kansas City, Kansas + 10 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
- Interventions
- IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose)
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
- Conditions
- Meningitis, Cryptococcal, HIV Infections
- Interventions
- Fluconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- Oakland, California • Chicago, Illinois • Brooklyn, New York + 2 more
- Conditions
- Thyroid Eye Disease
- Interventions
- VRDN-003, Autoinjector
- Drug · Device
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 13
- States / cities
- Inglewood, California • Cape Coral, Florida • Kissimmee, Florida + 7 more
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 5
- States / cities
- Duarte, California • Irvine, California • Denver, Colorado + 2 more
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- daclizumab, therapeutic allogeneic lymphocytes, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System Diseases
- Interventions
- Emapalumab, Fludarabine and Dexamethasone, Allogeneic hematopoietic stem cell transplant (allo-HCT)
- Drug · Procedure
- Lead sponsor
- Joseph Oved
- Other
- Eligibility
- Not listed
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- San Francisco, California • Atlanta, Georgia • Basking Ridge, New Jersey + 9 more
- Conditions
- Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
- Interventions
- ATLCAR.CD30 cells
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2037
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Winston-Salem, North Carolina
- Conditions
- Alcohol Use Disorder, Human Immunodeficiency Virus
- Interventions
- 4 week prebiotic consumption, 4 week placebo consumption
- Dietary Supplement · Other
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois